Efficient and Selective Prevention of GVHD by Antigen-Specific Induced Tregs via Linked-Suppression in Mice

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 3, 2011, Pages 309-318

  Semple, Kenrick ^a,b   Yu, Yu ^b   Wang, Dapeng ^b   Anasetti, Claudio ^a,b   Yu, Xue Zhong ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFIC INDUCED REGULATORY T CELL; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW TRANSPLANTATION; CD4+ CD25+ T LYMPHOCYTE; CELL COUNT; CELL INFILTRATION; CELL ISOLATION; CONTROLLED STUDY; EFFECTOR CELL; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; INTERMETHOD COMPARISON; LIVER CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; THERAPY EFFECT;

ANIMALS; ANIMALS, CONGENIC; ANTIGEN PRESENTATION; BONE MARROW TRANSPLANTATION; CELLS, CULTURED; CLONE CELLS; CROSSES, GENETIC; FORKHEAD TRANSCRIPTION FACTORS; GENES, REPORTER; GRAFT VS HOST DISEASE; IMMUNOSUPPRESSION; ISOANTIGENS; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, T-CELL; SURVIVAL ANALYSIS; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; WHOLE BODY IMAGING;

EID: 79551678785     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.12.710     Document Type: Article

References (46)

1. Appelbaum F.R. Haematopoietic cell transplantation as immunotherapy. Nature 2001, 411:385-389.
2. Shlomchik W.D. Graft-versus-host disease. Nat Rev 2007, 7:340-352.
3. Cohen J.L., Trenado A., Vasey D., Klatzmann D., Salomon B.L. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med 2002, 196:401-406.
4. Edinger M., Hoffmann P., Ermann J., et al. CD4+CD25+ regulatory T cells preserve graft- versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003, 9:1144-1150.
5. Ermann J., Hoffmann P., Edinger M., et al. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 2005, 105:2220-2226.
6. Hoffmann P., Ermann J., Edinger M., Fathman C.G., Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002, 196:389-399.
7. Taylor P.A., Panoskaltsis-Mortari A., Swedin J.M., et al. L-selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 2004, 104:3804-3812.
8. Trenado A., Charlotte F., Fisson S., et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft- versus-leukemia. J Clin Invest 2003, 112:1688-1696.
9. Di Ianni M., Falzetti F., Carotti A., et al. Adoptive immunotherapy with Tregs prevents GvHD and favours immune reconstitution after HLA haploidentical transplants for hematological malignancies. Blood (ASH Meeting Abstracts.) 2009, 114:4.
10. Curotto de Lafaille M.A., Lafaille J.J. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?. Immunity 2009, 30:626-635.
11. Albert M.H., Liu Y., Anasetti C., Yu X.Z. Antigen-dependent suppression of alloresponses by Foxp3-induced regulatory T cells in transplantation. Eur J Immunol 2005, 35:2598-2607.
12. Chai J.G., Xue S.A., Coe D., et al. Regulatory T cells, derived from naive CD4+CD25- T cells by in vitro Foxp3 gene transfer, can induce transplantation tolerance. Transplant 2005, 79:1310-1316.
13. Fu S., Zhang N., Yopp A.C., et al. TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25-precursors. Am J Transplant 2004, 4:1614-1627.
14. Gao W., Lu Y., El Essawy B., Oukka M., Kuchroo V.K., Strom T.B. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007, 7:1722-1732.
15. Koenecke C., Czeloth N., Bubke A., et al. Alloantigen-specific de novo-induced Foxp3(+) Treg revert in vivo and do not protect from experimental GVHD. Eur J Immunol 2009, 39:3091-3096.
16. DiPaolo R.J., Brinster C., Davidson T.S., Andersson J., Glass D., Shevach E.M. Autoantigen- specific TGFbeta-induced Foxp3+ regulatory T cells prevent autoimmunity by inhibiting dendritic cells from activating autoreactive T cells. J Immunol 2007, 179:4685-4693.
17. Tang Q., Henriksen K.J., Bi M., et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004, 199:1455-1465.
18. Zhang H., Podojil J.R., Chang J., Luo X., Miller S.D. TGF-beta-induced myelin peptide-specific regulatory T cells mediate antigen-specific suppression of induction of experimental autoimmune encephalomyelitis. J Immunol 2010, 184:6629-6636.
19. Fontenot J.D., Rasmussen J.P., Williams L.M., Dooley J.L., Farr A.G., Rudensky A.Y. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005, 22:329-341.
20. Fontenot J.D., Rasmussen J.P., Gavin M.A., Rudensky A.Y. A function for interleukin 2 in Foxp3- expressing regulatory T cells. Nat Immunol 2005, 6:1142-1151.
21. Negrin R.S., Contag C.H. In vivo imaging using bioluminescence: a tool for probing graft- versus-host disease. Nat Rev 2006, 6:484-490.
22. Guo F., Iclozan C., Suh W.K., Anasetti C., Yu X.Z. CD28 controls differentiation of regulatory T cells from naive CD4 T cells. J Immunol 2008, 181:2285-2291.
23. Iclozan C., Yu Y., Liu C., et al. Th17 cells are sufficient but not necessary to induce acute graft- versus-host disease. Biol Blood Marrow Transplant 2010, 16:170-178.
24. Liang Y., Liu C., Djeu J.Y., et al. Beta2 integrins separate graft-versus-host disease and graft- versus-leukemia effects. Blood 2008, 111:954-962.
25. Chen W., Jin W., Hardegen N., et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003, 198:1875-1886.
26. Zheng S.G., Wang J., Wang P., Gray J.D., Horwitz D.A. IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol 2007, 178:2018-2027.
27. Riley J.L., June C.H., Blazar B.R. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 2009, 30:656-665.
28. Golovina T.N., Mikheeva T., Suhoski M.M., et al. CD28 costimulation is essential for human T regulatory expansion and function. J Immunol 2008, 181:2855-2868.
29. Hoffmann P., Eder R., Kunz-Schughart L.A., Andreesen R., Edinger M. Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood 2004, 104:895-903.
30. Feuerer M., Hill J.A., Mathis D., Benoist C. Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol 2009, 10:689-695.
31. Floess S., Freyer J., Siewert C., et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007, 5:e38.
32. Tran D.Q., Ramsey H., Shevach E.M. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007, 110:2983-2990.
33. Hill J.A., Hall J.A., Sun C.M., et al. Retinoic acid enhances Foxp3 induction indirectly by relieving inhibition from CD4+CD44hi Cells. Immunity 2008, 29:758-770.
34. Luo X., Tarbell K.V., Yang H., et al. Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A 2007, 104:2821-2826.
35. Selvaraj R.K., Geiger T.L. A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF- beta. J Immunol 2007, 179. 11 p following 1390.
36. Zang W., Lin M., Kalache S., et al. Inhibition of the alloimmune response through the generation of regulatory T cells by a MHC class II-derived peptide. J Immunol 2008, 181:7499-7506.
37. Zheng S.G., Wang J., Horwitz D.A. Cutting edge: Foxp3+CD4+CD25+ regulatory T cells induced by IL-2 and TGF-beta are resistant to Th17 conversion by IL-6. J Immunol 2008, 180:7112-7116.
38. Sawitzki B., Kingsley C.I., Oliveira V., Karim M., Herber M., Wood K.J. IFN-gamma production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. J Exp Med 2005, 201:1925-1935.
39. Joffre O., Santolaria T., Calise D., et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 2008, 14:88-92.
40. Bushell A., Jones E., Gallimore A., Wood K. The generation of CD25+ CD4+ regulatory T cells that prevent allograft rejection does not compromise immunity to a viral pathogen. J Immunol 2005, 174:3290-3297.
41. Taylor P.A., Lees C.J., Blazar B.R. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002, 99:3493-3499.
42. Trenado A., Sudres M., Tang Q., et al. Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. J Immunol 2006, 176:1266-1273.
43. Yamazaki S., Patel M., Harper A., et al. Effective expansion of alloantigen-specific Foxp3+ CD25+ CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction. Proc Natl Acad Sci U S A 2006, 103:2758-2763.
44. Choi J., Ritchey J., Prior J.L., et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 2010, 116:129-139.
45. Sanchez-Abarca L.I., Gutierrez-Cosio S., Santamaria C., et al. Immunomodulatory effect of 5- azacytidine (5-azaC): potential role in the transplantation setting. Blood 2010, 115:107-121.
46. Zhao D., Zhang C., Yi T., et al. In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. Blood 2008, 112:2129-2138.